


Author Index

- Ambrose, M.W., see Gilbert, B.E. (17) 33
 Armstrong, J.A., see O'Marro, S.D. (17) 169
 Asuncion, C., see O'Marro, S.D. (17) 169
- Baba, M., Shigeta, S., Tanaka, H., Miyasaka, T., Ubasawa, M., Umezu, K., Walker, R.T., Pauwels, R., De Clercq, E., Highly potent and selective inhibition of HIV-1 replication by 6-phenylthiouracil derivatives (17) 245
 Balzarini, J., see Perno, C.-F. (17) 289
 Barnard, D.L., Huffman, J.H., Morris, J.L.B., Wood, S.G., Hughes, B.G., Sidwell, R.W., Evaluation of the antiviral activity of anthraquinones, anthrones and anthraquinone derivatives against human cytomegalovirus (17) 63
 Benson, J.D., see Huang, E.-S. (17) 17
 Bergamini, A., see Perno, C.-F. (17) 289
 Bradstreet, P., see Lebwohl, M. (17) 235
 Burger, R.A., see Morrey, J.D. (17) 223
- Calio, R., see Perno, C.-F. (17) 289
 Chen, V., see Lebwohl, M. (17) 235
 Cohen, J.S., see Kinchington, D. (17) 53
 Conant, M., see Lebwohl, M. (17) 235
 Connor, J., see Lebwohl, M. (17) 235
- De Clercq, E., see Perno, C.-F. (17) 289
 De Clercq, E., see Baba, M. (17) 245
 Decker, R.S., see Volsky, D.J. (17) 335
 Degols, G., Leonetti, J.-P., Milhaud, P., Mechti, N., Lebleu, B., Antisense inhibitors of HIV: problems and perspectives (17) 279
 Devine, K.G., see McGuigan, C. (17) 311
 Douglas Jr., J.M., see Lebwohl, M. (17) 235
- Eron, L., see Lebwohl, M. (17) 235
- Faras, A.J., see Ostrow, R.S. (17) 99
 Fedorczyk, D., see Lebwohl, M. (17) 235
 Forslund, K.M., see Ostrow, R.S. (17) 99
 Fox, J.J., see Trousdale, M.D. (17) 157
 Fraser-Smith, E.B., see Idowu, A.D. (17) 145
- Galpin, S., see Kinchington, D. (17) 53
 Gehr, R.C., Nelson, C.M., Kari, B.E., A combination of human cytomegalovirus (HCMV)-specific murine monoclonal antibodies exhibit synergistic antiviral activity in vitro (17) 115
 Ghosh, K., see Kinchington, D. (17) 53
 Gilbert, B.E., Wyde, P.R., Ambrose, M.W., Wilson, S.Z., Knight, V., Further studies with short duration ribavirin aerosol for the treatment of influenza virus infection in mice and respiratory syncytial virus infection in cotton rats (17) 33
 Gueverra, L., see O'Marro, S.D. (17) 169
- Hamblet, N., see Volsky, D.J. (17) 335
 Hay, A.J., see McGuigan, C. (17) 311
 Hayashi, K., Nishino, H., Niwayama, S., Shiraki, K., Hiramatsu, A., Yucca leaf protein (YLP) stops the protein synthesis in HSV-infected cells and inhibits virus replication (17) 323
 Hayden, F.G., see Sperber, S.J. (17) 213
 Herman, R.C., see Idowu, A.D. (17) 145
 Herrmann, G., see Lin, J.-C. (17) 43
 Hiramatsu, A., see Hayashi, K. (17) 323
 Ho, M., see O'Marro, S.D. (17) 169
 Huang, E.-S., Benson, J.D., Huong, S.-m., Wilson, B., van der Horst, C., Irreversible inhibition of human cytomegalovirus replication by topoisomerase II inhibitor, etoposide: a new strategy for the treatment of human cytomegalovirus infection (17) 17
 Huffman, J.H., see Barnard, D.L. (17) 63
 Huggins, J.W., see Ostrow, R.S. (17) 99
 Hughes, B.G., see Barnard, D.L. (17) 63
 Huong, S.-m., see Huang, E.-S. (17) 17
 Idowu, A.D., Fraser-Smith, E.B., Poffenberger, K.L., Herman, R.C., Deletion of the herpes simplex virus type 1 ribonucleotide reductase gene alters virulence and latency in vivo (17) 145
- Ijichi, K., see Machida, H. (17) 133
- Jaroszewski, J.W., see Kinchington, D. (17) 53
- Kari, B.E., see Gehr, R.C. (17) 115
 Kinchington, D., Galpin, S., Jaroszewski, J.W., Ghosh, K., Subasinghe, C., Cohen, J.S., A comparison of gag, pol and rev antisense oligodeoxynucleotides as inhibitors of HIV-1 (17) 53
 Kinchington, D., see McGuigan, C. (17) 197
 Knight, V., see Gilbert, B.E. (17) 33
 Kumura, K., see Ochiai, H. (17) 1
- Lamon, E.W., see Lidin, B. (17) 79
 Law, J.L., see Trousdale, M.D. (17) 157
 Lebleu, B., see Degols, G. (17) 279
 Lebwohl, M., Sacks, S., Conant, M., Connor, J., Douglas Jr., J.M., Eron, L., Marlowe, S.,

- Mendelson, J., Chen, V., Bradstreet, P., Fedorczyk, D., Trout, J.R., Plasse, T., Recombinant alpha-2 interferon gel treatment of recurrent herpes genitalis (17) 235
- Leonetti, J.-P., see Degols, G. (17) 279
- Li, G., see Volsky, D.J. (17) 335
- Lidin, B., Lamon, E.W., Differential effects of human recombinant interferons on the expression of two early gene products of Epstein-Barr virus (17) 79
- Lin, J.-C., Reefschräger, J., Herrmann, G., Pagano, J.S., Structure-activity relationship between (E)-5-(2-bromovinyl)- and 5-vinyl-1- β -D-arabinofuranosyluracil (BV-araU, V-araU) in inhibition of Epstein-Barr virus replication (17) 43
- Lown, J.W., Lexitropsins in antiviral drug development (Mini-Review) (17) 179
- Machida, H., Ijichi, K., Takezawa, J., Efficacy of oral treatment with BV-araU against cutaneous infection with herpes simplex type 1 in shaved mice (17) 133
- Mahmood, N., see McGuigan, C. (17) 311
- Marlowe, S., see Lebwohl, M. (17) 235
- Martin, J.A., Recent advances in the design of HIV proteinase inhibitors (17) 265
- McGlennen, R.C., see Ostrow, R.S. (17) 99
- McGuigan, C., Nickson, C., O'Connor, T.J., Kinchington, D., Synthesis and anti-HIV activity of some novel lactyl and glycolyl phosphate derivatives (17) 197
- McGuigan, C., Pathirana, R.N., Mahmood, N., Devine, K.G., Hay, A.J., Aryl phosphate derivatives of AZT retain activity against HIV1 in cell lines which are resistant to the action of AZT (17) 311
- Mead, J.R., see Morrey, J.D. (17) 223
- Mechti, N., see Degols, G. (17) 279
- Mendelson, J., see Lebwohl, M. (17) 235
- Milanese, G., see Perno, C.-F. (17) 289
- Milhaud, P., see Degols, G. (17) 279
- Minamishima, Y., see Ochiai, H. (17) 1
- Miyasaka, T., see Baba, M. (17) 245
- Morrey, J.D., Mead, J.R., Warren, R.P., Okleberry, K.M., Burger, R.A., Sidwell, R.W., Elucidation of mode of retroviral-inhibitory effects of imexon through use of immune competent and severe combined immune deficiency (SCID) mice (17) 223
- Morris, J.L.B., see Barnard, D.L. (17) 63
- Nelson, C.M., see Gehr, R.C. (17) 115
- Nickson, C., see McGuigan, C. (17) 197
- Nishino, H., see Hayashi, K. (17) 323
- Niwayama, S., see Hayashi, K. (17) 323
- O'Connor, T.J., see McGuigan, C. (17) 197
- O'Marro, S.D., Armstrong, J.A., Asuncion, C., Gueverra, L., Ho, M., The effect of combinations of ampligen and zidovudine or dideoxyinosine against human immunodeficiency viruses in vitro (17) 169
- Ochiai, H., Kumura, K., Minamishima, Y., Murine cytomegalovirus DNA polymerase: purification, characterization and role in the antiviral activity of acyclovir (17) 1
- Okleberry, K.M., see Morrey, J.D. (17) 223
- Ostrow, R.S., Forslund, K.M., McGlennen, R.C., Shaw, D.P., Schlievert, P.M., Ussery, M.A., Huggins, J.W., Faras, A.J., Ribavirin mitigates wart growth in rabbits at early stages of infection with cottontail rabbit papillomavirus (17) 99
- Pagano, J.S., see Lin, J.-C. (17) 43
- Pathirana, R.N., see McGuigan, C. (17) 311
- Pauwels, R., see Baba, M. (17) 245
- Pauwels, R., see Perno, C.-F. (17) 289
- Pellegrino, M.G., see Volsky, D.J. (17) 335
- Perno, C.-F., Yarchoan, R., Balzarini, J., Bergamini, A., Milanese, G., Pauwels, R., De Clercq, E., Rocchi, G., Calio, R., Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages (17) 289
- Plasse, T., see Lebwohl, M. (17) 235
- Poffenberger, K.L., see Idowu, A.D. (17) 145
- Potash, M.J., see Volsky, D.J. (17) 335
- Reefschräger, J., see Lin, J.-C. (17) 43
- Rocchi, G., see Perno, C.-F. (17) 289
- Sacks, S., see Lebwohl, M. (17) 235
- Schlievert, P.M., see Ostrow, R.S. (17) 99
- Schooley, R.T., Challenges in the clinical development of antiretroviral drugs (17) 305
- Shaw, D.P., see Ostrow, R.S. (17) 99
- Shigeta, S., see Baba, M. (17) 245
- Shiraki, K., see Hayashi, K. (17) 323
- Sidwell, R.W., see Barnard, D.L. (17) 63
- Sidwell, R.W., see Morrey, J.D. (17) 223
- Smith, B.V., see Sperber, S.J. (17) 213
- Sperber, S.J., Smith, B.V., Hayden, F.G., Serologic response and reactogenicity to booster immunization of healthy seropositive adults with live or inactivated varicella vaccine (17) 213
- Subasinghe, C., see Kinchington, D. (17) 53
- Takezawa, J., see Machida, H. (17) 133
- Tanaka, H., see Baba, M. (17) 245
- Trousdale, M.D., Law, J.L., Yarber, F.A., Watanabe, K.A., Fox, J.J., Evaluation of 1-(2'-deoxy-

- 2'-fluoro- β -D-arabinofuranosyl)-5-ethyluracil in
a rabbit model of herpetic keratitis (17) 157
Trout, J.R., see Lebwohl, M. (17) 235
- Ubasawa, M., see Baba, M. (17) 245
Umezu, K., see Baba, M. (17) 245
Ussery, M.A., see Ostrow, R.S. (17) 99
- van der Horst, C., see Huang, E.-S. (17) 17
Volsky, B., see Volsky, D.J. (17) 335
Volsky, D.J., Li, G., Hamblet, N., Volsky, B.,
Decker, R.S., Pellegrino, M.G., Potash, M.J.,
Evaluation of multiple parameters of HIV-1
replication cycle in testing of AIDS drugs in
vitro (17) 335
- Walker, R.T., see Baba, M. (17) 245
Warren, R.P., see Morrey, J.D. (17) 223
Watanabe, K.A., see Trousdale, M.D. (17) 157
Wilson, B., see Huang, E.-S. (17) 17
Wilson, S.Z., see Gilbert, B.E. (17) 33
Wood, S.G., see Barnard, D.L. (17) 63
Wyde, P.R., see Gilbert, B.E. (17) 33
- Yarber, F.A., see Trousdale, M.D. (17) 157
Yarchoan, R., see Perno, C.-F. (17) 289



Subject Index

- ACV triphosphate;** Murine cytomegalovirus (MCMV); DNA polymerase; Kinetic constant; Acyclovir (ACV) (17) 1
- Acyclovir (ACV);** ACV triphosphate; Murine cytomegalovirus (MCMV); DNA polymerase; Kinetic constant (17) 1
- Aerosol;** Respiratory syncytial virus; Influenza; Animal; Ribavirin (17) 33
- AIDS;** Antiviral; Drug resistance; Azidothymidine; Zidovudine; Dideoxyinosine; Human immunodeficiency virus (17) 169
- AIDS;** HIV; Friend virus; Severe combined immune deficient (SCID) mice; Biological response modifier (BRM); Imexon (17) 223
- Animal;** Ribavirin; Aerosol; Respiratory syncytial virus; Influenza (17) 33
- Anthraquinone;** Hypericin; Cytotoxicity; Virucidal; Human cytomegalovirus (17) 63
- Anti-HIV drug;** Cytokine; HIV; Macrophage; Lymphocyte (17) 289
- Anti-HSV activity;** Viral penetration; Protein synthesis inhibition; Yucca leaf protein (17) 323
- Antigene;** Antisense; Lexitropsin; Sequence selective; Drug development (17) 179
- Antisense;** Gag; HIV; Oligodeoxynucleotide; Phosphorothioate; Pol; Rev (17) 53
- Antisense;** Lexitropsin; Sequence selective; Drug development; Antigene (17) 179
- Antiviral;** Drug resistance; Azidothymidine; Zidovudine; Dideoxyinosine; Human immunodeficiency virus; AIDS (17) 169
- Antiviral;** Ocular disease; Herpesvirus; FEAU (17) 157
- Azidothymidine;** Zidovudine; Dideoxyinosine; Human immunodeficiency virus; AIDS; Antiviral; Drug resistance (17) 169
- AZT;** Nucleotide; Pro-drug; HIV (17) 311
- AZT;** Nucleotide; Pro-drug; Lactate; Glycolate; HIV (17) 197
- Biological response modifier (BRM);** Imexon; AIDS; HIV; Friend virus; Severe combined immune deficient (SCID) mice (17) 223
- BV-araU;** HSV-1; Mouse model; Skin infection; Immunocompromised (17) 133
- BV-araU;** V-araU; Epstein-Barr virus; EBV (17) 43
- Chronic infection;** Multiple parameter evaluation; Human immunodeficiency virus; Reverse transcriptase inhibitor (17) 335
- Cytokine;** HIV; Macrophage; Lymphocyte; Anti-HIV drug (17) 289
- Cytotoxicity;** Virucidal; Human cytomegalovirus; Anthraquinone; Hypericin (17) 63
- Dideoxyinosine;** Human immunodeficiency virus; AIDS; Antiviral; Drug resistance; Azidothymidine; Zidovudine (17) 169
- DNA polymerase;** Kinetic constant; Acyclovir (ACV); ACV triphosphate; Murine cytomegalovirus (MCMV) (17) 1
- Drug development;** Antigene; Antisense; Lexitropsin; Sequence selective (17) 179
- Drug resistance;** Azidothymidine; Zidovudine; Dideoxyinosine; Human immunodeficiency virus; AIDS; Antiviral (17) 169
- EBV;** BV-araU; V-araU; Epstein-Barr virus (17) 43
- Enzyme inhibition;** Transition-state analog; Peptide mimetic; HIV proteinase (17) 265
- Epstein-Barr virus;** EBV; BV-araU; V-araU (17) 43
- Etoposide;** Infection; Topoisomerase II; Human cytomegalovirus (17) 17
- FEAU;** Antiviral; Ocular disease; Herpesvirus (17) 157
- Friend virus;** Severe combined immune deficient (SCID) mice; Biological response modifier (BRM); Imexon; AIDS; HIV (17) 223
- Gag;** HIV; Oligodeoxynucleotide; Phosphorothioate; Pol; Rev; Antisense (17) 53
- Glycolate;** HIV; AZT; Nucleotide; Pro-drug; Lactate (17) 197
- Herpes genitalis;** Interferon; Topical (17) 235
- Herpes simplex virus type 1;** Virulence; Latency; Ribonucleotide reductase (17) 145
- Herpesvirus;** FEAU; Antiviral; Ocular disease (17) 157
- HIV proteinase;** Enzyme inhibition; Transition-state analog; Peptide mimetic (17) 265
- HIV;** AZT; Nucleotide; Pro-drug (17) 311
- HIV;** AZT; Nucleotide; Pro-drug; Lactate; Glycolate (17) 197
- HIV;** Friend virus; Severe combined immune deficient (SCID) mice; Biological response modifier (BRM); Imexon; AIDS (17) 223
- HIV;** Macrophage; Lymphocyte; Anti-HIV drug; Cytokine (17) 289
- HIV;** Oligodeoxynucleotide; Phosphorothioate; Pol; Rev; Antisense; Gag (17) 53

- HIV-1 replication inhibition;** 6-Phenylthiouracil derivative (17) 245
- HSV-1;** Mouse model; Skin infection; Immuno-compromised; BV-araU (17) 133
- Human cytomegalovirus, HCMV;** Monoclonal antibody, HCMV-specific; Monoclonal antibody (17) 115
- Human cytomegalovirus;** Anthraquinone; Hypericin; Cytotoxicity; Virucidal (17) 63
- Human cytomegalovirus;** Etoposide; Infection; Topoisomerase II (17) 17
- Human immunodeficiency virus;** AIDS; Antiviral; Drug resistance; Azidothymidine; Zidovudine; Dideoxyinosine (17) 169
- Human immunodeficiency virus;** Reverse transcriptase inhibitor; Chronic infection; Multiple parameter evaluation (17) 335
- Hypericin;** Cytotoxicity; Virucidal; Human cytomegalovirus; Anthraquinone (17) 63
- Imexon;** AIDS; HIV; Friend virus; Severe combined immune deficient (SCID) mice; Biological response modifier (BRM) (17) 223
- Immunocompromised;** BV-araU; HSV-1; Mouse model; Skin infection (17) 133
- Infection;** Topoisomerase II; Human cytomegalovirus; Etoposide (17) 17
- Influenza;** Animal; Ribavirin; Aerosol; Respiratory syncytial virus (17) 33
- Interferon;** Topical; Herpes genitalis (17) 235
- Kinetic constant;** Acyclovir (ACV); ACV triphosphate; Murine cytomegalovirus (MCMV); DNA polymerase (17) 1
- Lactate;** Glycolate; HIV; AZT; Nucleotide; Pro-drug (17) 197
- Latency;** Ribonucleotide reductase; Herpes simplex virus type 1; Virulence (17) 145
- Lexitropsin;** Sequence selective; Drug development; Antigene; Antisense (17) 179
- Lymphocyte;** Anti-HIV drug; Cytokine; HIV; Macrophage (17) 289
- Macrophage;** Lymphocyte; Anti-HIV drug; Cytokine; HIV (17) 289
- Monoclonal antibody, HCMV-specific;** Monoclonal antibody; Human cytomegalovirus, HCMV (17) 115
- Monoclonal antibody;** Human cytomegalovirus, HCMV; Monoclonal antibody, HCMV-specific (17) 115
- Mouse model;** Skin infection; Immunocompromised; BV-araU; HSV-1 (17) 133
- Multiple parameter evaluation;** Human immunodeficiency virus; Reverse transcriptase inhibitor; Chronic infection (17) 335
- Murine cytomegalovirus (MCMV);** DNA polymerase; Kinetic constant; Acyclovir (ACV); ACV triphosphate (17) 1
- Nucleotide;** Pro-drug; HIV; AZT (17) 311
- Nucleotide;** Pro-drug; Lactate; Glycolate; HIV; AZT (17) 197
- Ocular disease;** Herpesvirus; FEAU; Antiviral (17) 157
- Oligodeoxynucleotide;** Phosphorothioate; Pol; Rev; Antisense; Gag; HIV (17) 53
- Papillomavirus;** Ribavirin; Rabbit; Wart inhibition (17) 99
- Peptide mimetic;** HIV proteinase; Enzyme inhibition; Transition-state analog (17) 265
- 6-Phenylthiouracil derivative;** HIV-1 replication inhibition (17) 245
- Phosphorothioate;** Pol; Rev; Antisense; Gag; HIV; Oligodeoxynucleotide (17) 53
- Pol;** Rev; Antisense; Gag; HIV; Oligodeoxynucleotide; Phosphorothioate (17) 53
- Pro-drug;** HIV; AZT; Nucleotide (17) 311
- Pro-drug;** Lactate; Glycolate; HIV; AZT; Nucleotide (17) 197
- Protein synthesis inhibition;** Yucca leaf protein; Anti-HSV activity; Viral penetration (17) 323
- Rabbit;** Wart inhibition; Papillomavirus; Ribavirin (17) 99
- Respiratory syncytial virus;** Influenza; Animal; Ribavirin; Aerosol (17) 33
- Rev;** Antisense; Gag; HIV; Oligodeoxynucleotide; Phosphorothioate; Pol (17) 53
- Reverse transcriptase inhibitor;** Chronic infection; Multiple parameter evaluation; Human immunodeficiency virus (17) 335
- Ribavirin;** Aerosol; Respiratory syncytial virus; Influenza; Animal (17) 33
- Ribavirin;** Rabbit; Wart inhibition; Papillomavirus (17) 99
- Ribonucleotide reductase;** Herpes simplex virus type 1; Virulence; Latency (17) 145
- Sequence selective;** Drug development; Antigene; Antisense; Lexitropsin (17) 179
- Severe combined immune deficient (SCID) mice;** Biological response modifier (BRM); Imexon; AIDS; HIV; Friend virus (17) 223
- Skin infection;** Immunocompromised; BV-araU; HSV-1; Mouse model (17) 133
- Topical;** Herpes genitalis; Interferon (17) 235
- Topoisomerase II;** Human cytomegalovirus; Etoposide; Infection (17) 17

Transition-state analog; Peptide mimetic; HIV proteinase; Enzyme inhibition (17) 265

V-araU; Epstein-Barr virus; EBV; BV-araU (17) 43

Viral penetration; Protein synthesis inhibition; Yucca leaf protein; Anti-HSV activity (17) 323

Virucidal; Human cytomegalovirus; Anthraquinone; Hypericin; Cytotoxicity (17) 63

Virulence; Latency; Ribonucleotide reductase; Herpes simplex virus type 1 (17) 145

Wart inhibition; Papillomavirus; Ribavirin; Rabbit (17) 99

Yucca leaf protein; Anti-HSV activity; Viral penetration; Protein synthesis inhibition (17) 323

Zidovudine; Dideoxyinosine; Human immunodeficiency virus; AIDS; Antiviral; Drug resistance; Azidothymidine (17) 169